In last trading session, Intellia Therapeutics, Inc. (NASDAQ:NTLA) saw 1,568,572 shares changing hands with its beta currently measuring 2.09. Company’s recent per share price level of $76.01 trading at $0.32 or 0.42% at ring of the bell on the day assigns it a market valuation of $4.91 Billion. That closing price of NTLA’s stock is at a discount of -13.31% from its 52-week high price of $86.13 and is indicating a premium of 87.92% from its 52-week low price of $9.18. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.14 Million shares which gives us an average trading volume of 1.42 Million if we extend that period to 3-months.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

For Intellia Therapeutics, Inc. (NTLA), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2.2. Splitting up the data highlights that, out of 14 analysts covering the stock, none rated the stock as a Sell while 2 recommended an Overweight rating for the stock. 5 suggested the stock as a Hold whereas 7 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.61 in the current quarter.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) trade information

Upright in the green during last session for gaining 0.42%, in the last five days NTLA remained trading in the green while hitting it’s week-highest on Friday, Jan 08 when the stock touched $86.13- price level, adding 11.75% to its value on the day. Intellia Therapeutics, Inc.’s shares saw a change of 39.72% in year-to-date performance and have moved 13.89% in past 5-day. Intellia Therapeutics, Inc. (NASDAQ:NTLA) showed a performance of 42.71% in past 30-days. Number of shares sold short was 10.15 Million shares which calculate 7.15 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $66.88 to the stock, which implies targetted prices is already lagging behind -12.01% to its current value. Analysts have been projecting $22 as a low price target for the stock while placing it at a high target of $109. It follows that stock’s current price would jump +43.4% in reaching the projected high whereas dropping to the targeted low would mean a loss of -71.06% for stock’s current value.

Intellia Therapeutics, Inc. (NTLA) estimates and forecasts

Statistics highlight that Intellia Therapeutics, Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added +236.18% of value to its shares in past 6 months, showing an annual growth rate of -7.58% while that of industry is 14.5. Apart from that, the company came lowering its revenue forecast for fiscal year 2021. The company is estimating its revenue growth to decline by -7% in the current quarter and calculating -15.9% decline in the next quarter. This year revenue growth is estimated to rise 53.5% from the last financial year’s standing.

11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $14.09 Million for the same. And 7 analysts are in estimates of company making revenue of $11.56 Million in the next quarter that will end on March 01, 2021. Company posted $10.94 Million of sales in current quarter a year earlier. Analysts are expecting this quarter sales to grow by 28.8%.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -50.6% during past 5 years. In 2021, company’s earnings growth rate is likely to be around -6.3% while estimates for its earnings growth in next 5 years are of 30%

Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s Major holders

Insiders are in possession of 13.58% of company’s total shares while institution are holding 85.75% percent of that, with stock having share float percentage of 99.22%. Investors also watch the number of corporate investors in a company very closely, which is 249 institutions for Intellia Therapeutics, Inc. that are currently holding shares of the company. ARK Investment Management, LLC is the top institutional holder at NTLA for having 11.4 Million shares of worth $226.73 Million. And as of September 29, 2020, it was holding 19.3% of the company’s outstanding shares.

The second largest institutional holder is Nikko Asset Management Americas, Inc., which was holding about 6.06 Million shares on September 29, 2020. The number of shares represents firm’s hold over 10.26% of outstanding shares, having a total worth of $120.52 Million.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

On the other hand, ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF are the top two Mutual Funds which own company’s shares. As of December 30, 2020, the former fund manager was holding 6603257 shares of worth $359.22 Million or 11.18% of the total outstanding shares. The later fund manager was in possession of 2.18 Million shares on December 30, 2020, making its stake of worth around $118.53 Million in the company or a holder of 3.69% of company’s stock.

A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on..

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.


Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free


Please enter your comment!
Please enter your name here